Boron-Containing PDE4 Inhibitors for Inflammatory Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases such as atopic dermatitis, psoriasis, and inflammatory bowel disease are often unsatisfactory due to limited efficacy and adverse side effects, highlighting a need for new therapeutic methods that can effectively modulate inflammatory processes.
Innovation Solution
Development of boron-containing compounds that inhibit phosphodiesterase 4 (PDE4), which are used in pharmaceutical compositions to treat or prevent inflammatory disorders by modulating inflammatory cytokine levels, thereby addressing the limitations of existing treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for inflammatory diseases are used, then they can address some symptoms, but they have limited efficacy and cause adverse side effects
Solution Approach 1:
The patent employs parameter changes by developing novel boron-containing chemical compounds with specific molecular structures (Formula I) that selectively inhibit PDE4 enzyme. This chemical parameter change creates a new therapeutic agent with improved efficacy profile and reduced side effects compared to existing treatments for inflammatory diseases
Solution Approach 2:
The invention uses composite material principles by creating complex boron-containing compounds that combine multiple functional groups (aromatic rings, heterocycles, boron coordination spheres) into a single molecular entity. This composite molecular structure enables selective PDE4 inhibition with optimized pharmacological properties
2Reliability
If new therapeutic methods are developed to improve efficacy, then treatment effectiveness increases, but complexity of treatment increases
Solution Approach 1:
The patent applies the extraction principle by specifically targeting and inhibiting the PDE4 enzyme isoform among the PDE enzyme family. This selective extraction of PDE4 inhibition provides improved efficacy for inflammatory diseases while maintaining simpler treatment regimens compared to non-selective approaches
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to boron containing compounds of Formula (I) X-Y-Z Formula (I) that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.